As the U.S. stock market navigates a period of uncertainty with the Federal Reserve's interest rate decision looming, investors are keenly focused on potential opportunities within various sectors.

Lynx1 Master Fund LP (together with its affiliates, "Lynx1"), the beneficial owner of 875,328 shares of common stock, par value $0.00001 per share ("Common Stock"), of Neuphoria Therapeutics Inc., a ...